Brief: Histogen Says Phase 1/2 Trial Initiation For Knee Cartilage Regeneration Anticipated In Q1 2021
17/12/2020 14:49
Dec 17 (Reuters) - Histogen Inc HSTO.O :
* HISTOGEN ANNOUNCES FILING AN INVESTIGATIONAL NEW DRUG
APPLICATION FOR HST-003
* HISTOGEN INC - PHASE 1/2 TRIAL INITIATION FOR KNEE
CARTILAGE
REGENERATION ANTICIPATED IN Q1 2021
Source text for Eikon: ID:nGNXKWTPr
Further company coverage: HSTO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Histogen
See all newsBrief: Histogen Announces Second Adjournment Of Special Meeting Of Stockholders
Brief: Histogen Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Histogen Announces Board Approval Of Complete Liquidation And Dissolution
Histogen Inc expected to post a loss of 90 cents a share - Earnings Preview
Histogen to explore strategic options, shares up